Clinical testing of the coronavirus vaccine by the University of Oxford and the company AstraZeneca resumed after the Medicines and Health Products Regulatory Agency (MHRA) confirmed that it was safe to do so, the British company reported.

AstraZeneca announced last Tuesday that it had decided to stop the trial of the vaccine it is developing against COVID-19 due to the appearance of “a potentially inexplicable disease” in one of its participants.

“The standard review process resulted in a voluntary pause in vaccination in all global trials to allow for review of safety data by independent international regulatory and committees,” said AstraZeneca.

“The UK committee concluded its investigation and told the MHRA that it was safe to resume testing in the UK,” the company added.

The company said it could not release further medical information.

“All investigators and trial participants will receive the relevant information and this will also be disclosed in global clinical registries, in accordance with all regulatory and clinical testing standards,” added AstraZeneca.

“It is a routine action that has to be done whenever there is a potentially unexplained illness in one of the trials, ensuring that we maintain the integrity” of the trials, AstraZeneca concludes.

AstraZeneca already has contracts with the United Kingdom, the United States and the EU for the supply of doses of its vaccine once the testing phase is completed.